RT Journal Article
SR Electronic
T1 COVID-19 vaccine effectiveness against mortality and risk of death from other causes after COVID-19 vaccination, the Netherlands, January 2021-January 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.21.22277831
DO 10.1101/2022.07.21.22277831
A1 de Gier, Brechje
A1 van Asten, Liselotte
A1 Boere, Tjarda
A1 van Roon, Annika
A1 van Roekel, Caren
A1 Pijpers, Joyce
A1 van Werkhoven, Henri
A1 van den Ende, Caroline
A1 Hahné, Susan
A1 de Melker, Hester
A1 Knol, Mirjam
A1 van den Hof, Susan
YR 2023
UL http://medrxiv.org/content/early/2023/02/13/2022.07.21.22277831.abstract
AB Background We aimed to estimate vaccine effectiveness (VE) against COVID-19 mortality, and to explore whether an increased risk in non-COVID-19 mortality exists in the weeks following a COVID-19 vaccine dose.Methods National registries of causes of death, COVID-19 vaccination, specialized health care and long-term care reimbursements were linked by a unique identifier using data from 1 January 2021 to 31 January 2022. We used Cox regression with calendar time as underlying time scale to: 1) estimate VE against COVID-19 mortality after primary and first booster vaccination, per month since vaccination and 2) estimate risk of non-COVID-19 mortality in the 8 weeks following a first, second or first booster dose, adjusting for birth year, sex, medical risk group and country of origin.Results VE against COVID-19 mortality was >90% for all age groups two months after completion of the primary series. VE gradually decreased thereafter, to around 80% at 7-8 months post-primary series for most groups, and around 60% for elderly receiving a high level of long-term care and for people aged 90+ years. Following a first booster dose, the VE increased to >85% in all groups. The risk of non-COVID-19 mortality was lower or similar in the 8 weeks following a first primary, second primary or first booster dose compared to no vaccination, first or second dose, respectively, for all age and long-term care groups.Conclusion COVID-19 vaccination greatly reduced the risk of COVID-19 mortality and no increased risk of death from other causes was seen at the population level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Dutch Ministry of Health, Welfare and Sports.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Centre for Clinical Expertise at the RIVM assessed the research proposal. They verified whether the work complies with the specific conditions as stated in the law for medical research involving human subjects (WMO), and were of the opinion that the research does not fulfill one or both of these conditions and therefore conclude it is exempted for further approval by the ethical research committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUnder certain conditions, these microdata are accessible for statistical and scientific research. For further information: microdata -at- cbs.nl.